189 related articles for article (PubMed ID: 23458554)
1. Sinusoidal obstruction syndrome (SOS) related to chemotherapy for colorectal liver metastases: factors predictive of severe SOS lesions and protective effect of bevacizumab.
Hubert C; Sempoux C; Humblet Y; van den Eynde M; Zech F; Leclercq I; Gigot JF
HPB (Oxford); 2013 Nov; 15(11):858-64. PubMed ID: 23458554
[TBL] [Abstract][Full Text] [Related]
2. Predicting high grade lesions of sinusoidal obstruction syndrome related to oxaliplatin-based chemotherapy for colorectal liver metastases: correlation with post-hepatectomy outcome.
Soubrane O; Brouquet A; Zalinski S; Terris B; Brézault C; Mallet V; Goldwasser F; Scatton O
Ann Surg; 2010 Mar; 251(3):454-60. PubMed ID: 20160638
[TBL] [Abstract][Full Text] [Related]
3. Sinusoidal dilation increases the risk of complications in hepatectomy for CRCLM - Protective effect of bevacizumab and diabetes mellitus, serum gamma-glutamyltranspeptidase as predictive factor.
Martins J; Alexandrino H; Oliveira R; Cipriano MA; Falcão D; Ferreira L; Martins R; Serôdio M; Martins M; Tralhão JG; Prado e Castro L; Castro E Sousa F
Eur J Surg Oncol; 2016 May; 42(5):713-21. PubMed ID: 26972374
[TBL] [Abstract][Full Text] [Related]
4. von Willebrand Factor-Rich Platelet Thrombi in the Liver Cause Sinusoidal Obstruction Syndrome following Oxaliplatin-Based Chemotherapy.
Nishigori N; Matsumoto M; Koyama F; Hayakawa M; Hatakeyayama K; Ko S; Fujimura Y; Nakajima Y
PLoS One; 2015; 10(11):e0143136. PubMed ID: 26580395
[TBL] [Abstract][Full Text] [Related]
5. Splenic volume may be a useful indicator of the protective effect of bevacizumab against oxaliplatin-induced hepatic sinusoidal obstruction syndrome.
Imai K; Emi Y; Iyama KI; Beppu T; Ogata Y; Kakeji Y; Samura H; Oki E; Akagi Y; Maehara Y; Baba H;
Eur J Surg Oncol; 2014 May; 40(5):559-566. PubMed ID: 24388740
[TBL] [Abstract][Full Text] [Related]
6. Bevacizumab improves splenomegaly and decreases production of hyaluronic acid after L-OHP based chemotherapy.
Arakawa Y; Shimada M; Utsunomiya T; Imura S; Morine Y; Ikemoto T; Hanaoka J; Kanamoto M; Iwahashi S; Saito Y; Yamada S; Asanoma M; Takasu C; Bando Y
Anticancer Res; 2014 Apr; 34(4):1953-8. PubMed ID: 24692731
[TBL] [Abstract][Full Text] [Related]
7. Diagnostic performance of contrast-enhanced CT-scan in sinusoidal obstruction syndrome induced by chemotherapy of colorectal liver metastases: Radio-pathological correlation.
Cayet S; Pasco J; Dujardin F; Besson M; Orain I; De Muret A; Miquelestorena-Standley E; Thiery J; Genet T; Le Bayon AG
Eur J Radiol; 2017 Sep; 94():180-190. PubMed ID: 28712693
[TBL] [Abstract][Full Text] [Related]
8. Chemotherapy-induced Sinusoidal Injury (CSI) score: a novel histologic assessment of chemotherapy-related hepatic sinusoidal injury in patients with colorectal liver metastasis.
Stevenson HL; Prats MM; Sasatomi E
BMC Cancer; 2017 Jan; 17(1):35. PubMed ID: 28061766
[TBL] [Abstract][Full Text] [Related]
9. Sinusoidal obstruction syndrome and nodular regenerative hyperplasia are frequent oxaliplatin-associated liver lesions and partially prevented by bevacizumab in patients with hepatic colorectal metastasis.
Rubbia-Brandt L; Lauwers GY; Wang H; Majno PE; Tanabe K; Zhu AX; Brezault C; Soubrane O; Abdalla EK; Vauthey JN; Mentha G; Terris B
Histopathology; 2010 Mar; 56(4):430-9. PubMed ID: 20459550
[TBL] [Abstract][Full Text] [Related]
10. Impact of biological agents on the prevalence of chemotherapy associated liver injury (CALI): Multicentric study of patients operated for colorectal liver metastases.
Hubert C; Lucidi V; Weerts J; Dili A; Demetter P; Massart B; Komuta M; Navez J; Reding R; Gigot JF; Sempoux C
Eur J Surg Oncol; 2018 Oct; 44(10):1532-1538. PubMed ID: 30093084
[TBL] [Abstract][Full Text] [Related]
11. Liver injury due to chemotherapy-induced sinusoidal obstruction syndrome is associated with sinusoidal capillarization.
Narita M; Oussoultzoglou E; Chenard MP; Fuchshuber P; Rather M; Rosso E; Addeo P; Jaeck D; Bachellier P
Ann Surg Oncol; 2012 Jul; 19(7):2230-7. PubMed ID: 22402811
[TBL] [Abstract][Full Text] [Related]
12. Liver resection for colorectal metastases after chemotherapy: impact of chemotherapy-related liver injuries, pathological tumor response, and micrometastases on long-term survival.
Viganò L; Capussotti L; De Rosa G; De Saussure WO; Mentha G; Rubbia-Brandt L
Ann Surg; 2013 Nov; 258(5):731-40; discussion 741-2. PubMed ID: 24045448
[TBL] [Abstract][Full Text] [Related]
13. Pathogenesis of FOLFOX induced sinusoidal obstruction syndrome in a murine chemotherapy model.
Robinson SM; Mann J; Vasilaki A; Mathers J; Burt AD; Oakley F; White SA; Mann DA
J Hepatol; 2013 Aug; 59(2):318-26. PubMed ID: 23624001
[TBL] [Abstract][Full Text] [Related]
14. Bevacizumab protects against sinusoidal obstruction syndrome and does not increase response rate in neoadjuvant XELOX/FOLFOX therapy of colorectal cancer liver metastases.
Klinger M; Eipeldauer S; Hacker S; Herberger B; Tamandl D; Dorfmeister M; Koelblinger C; Gruenberger B; Gruenberger T
Eur J Surg Oncol; 2009 May; 35(5):515-20. PubMed ID: 19200687
[TBL] [Abstract][Full Text] [Related]
15. Accuracy of gadoxetic acid-enhanced magnetic resonance imaging for the diagnosis of sinusoidal obstruction syndrome in patients with chemotherapy-treated colorectal liver metastases.
Shin NY; Kim MJ; Lim JS; Park MS; Chung YE; Choi JY; Kim KW; Park YN
Eur Radiol; 2012 Apr; 22(4):864-71. PubMed ID: 22108766
[TBL] [Abstract][Full Text] [Related]
16. Preoperative assessment of chemotherapeutic associated liver injury based on indocyanine green retention test.
Russolillo N; Langella S; Perotti S; Lo Tesoriere R; Forchino F; Ferrero A
Int J Surg; 2016 Jul; 31():80-5. PubMed ID: 27260311
[TBL] [Abstract][Full Text] [Related]
17. Magnetic resonance assessment of sinusoidal obstruction syndrome after neoadjuvant chemotherapy for colorectal liver metastases is not reproducible.
Staal FC; Beets-Tan RG; Heeres BC; Houwers J; de Boer M; van Dorth D; Lambregts DM; Maas M
Acta Radiol; 2021 Sep; 62(9):1133-1141. PubMed ID: 32972213
[TBL] [Abstract][Full Text] [Related]
18. Hyaluronic acid as a marker of hepatic sinusoidal obstruction syndrome secondary to oxaliplatin-based chemotherapy in patients with colorectal liver metastases.
van den Broek MA; Vreuls CP; Winstanley A; Jansen RL; van Bijnen AA; Dello SA; Bemelmans MH; Dejong CH; Driessen A; Olde Damink SW
Ann Surg Oncol; 2013 May; 20(5):1462-9. PubMed ID: 23463086
[TBL] [Abstract][Full Text] [Related]
19. Hepatic Parenchymal Heterogeneity as a Marker for Oxaliplatin-Induced Sinusoidal Obstruction Syndrome: Correlation With Treatment Response of Colorectal Cancer Liver Metastases.
Han NY; Park BJ; Yang KS; Kim MJ; Sung DJ; Sim KC; Cho SB
AJR Am J Roentgenol; 2017 Nov; 209(5):1039-1045. PubMed ID: 28813196
[TBL] [Abstract][Full Text] [Related]
20. Hepatic sinusoidal obstruction syndrome (SOS) reduces the effect of oxaliplatin in colorectal liver metastases.
Vreuls CP; Van Den Broek MA; Winstanley A; Koek GH; Wisse E; Dejong CH; Olde Damink SW; Bosman FT; Driessen A
Histopathology; 2012 Aug; 61(2):314-8. PubMed ID: 22571348
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
